Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C1-esteraseremmer-N for Hereditary and Acquired Angioedema
NCT00125541Phase 3Completed
- Sponsor
- Prothya Biosolutions
- Start
- Nov 2006
- Primary completion
- Apr 2008
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of C1 inhibitor, human in hereditary angioedema (HAE) and acquired angioedema (AAE), sponsored by Prothya Biosolutions. Primary endpoint: Prevention of angioedema attacks at 16 weeks. Started Nov 2006; status: completed.
02
Drugs
C1 inhibitor, human
03
Conditions
hereditary angioedema (HAE)acquired angioedema (AAE)
Beyond the preview
Go deeper on NCT00125541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00125541.